Sun Pharmaceutical Industries Ltd. has announced its acquisition of US-based Checkpoint Therapeutics Inc. for $355 million. This move aims to strengthen Sun Pharma's specialty therapy portfolio, particularly in immunotherapy and oncology. The acquisition aligns with Sun Pharma’s strategy to expand its presence in advanced medical treatments. Checkpoint Therapeutics specializes in developing innovative cancer therapies, adding value to Sun Pharma’s existing pipeline. This deal reflects Sun Pharma’s ongoing commitment to enhancing its global pharmaceutical footprint. Continue here.
